CN111363829A - miRNA marker of bile duct cancer and application thereof - Google Patents

miRNA marker of bile duct cancer and application thereof Download PDF

Info

Publication number
CN111363829A
CN111363829A CN202010458316.0A CN202010458316A CN111363829A CN 111363829 A CN111363829 A CN 111363829A CN 202010458316 A CN202010458316 A CN 202010458316A CN 111363829 A CN111363829 A CN 111363829A
Authority
CN
China
Prior art keywords
mir
mirna
cholangiocarcinoma
duct cancer
bile duct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010458316.0A
Other languages
Chinese (zh)
Other versions
CN111363829B (en
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Xinnuo Weikang Technology Co ltd
Original Assignee
Beijing Xinnuo Weikang Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xinnuo Weikang Technology Co ltd filed Critical Beijing Xinnuo Weikang Technology Co ltd
Priority to CN202010458316.0A priority Critical patent/CN111363829B/en
Priority to CN202010799217.9A priority patent/CN111748635B/en
Publication of CN111363829A publication Critical patent/CN111363829A/en
Application granted granted Critical
Publication of CN111363829B publication Critical patent/CN111363829B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The application provides miRNA markers for diagnosing bile duct cancer and application thereof. The miRNA markers provided by the application comprise one or more of miR-151a-5p, miR-191-5p and miR-4732-3p, and can be used for rapidly and accurately screening, predicting, diagnosing or prognosing cholangiocarcinoma.

Description

miRNA marker of bile duct cancer and application thereof
Technical Field
The application belongs to the field of molecular biology, and particularly relates to a miRNA marker for screening, predicting, diagnosing or prognosing bile duct cancer and an application thereof.
Background
Exosomes are tiny membrane vesicles secreted by most cells in the body, with lipid bilayer membranes, approximately 30-150 nm in diameter. Exosomes are widely existed and distributed in various body fluids, carry and transmit important signal molecules, form a brand-new cell-cell information transmission system, influence the physiological state of cells and are closely related to the occurrence and the progress of various diseases.
Exosomes can directly promote growth, invasion and migration of tumor cells by serving as an intercellular communication mechanism, and the contained miRNA is an important functional molecule for transmitting information among cells. By screening and identifying small RNA in exosome secreted by tumor cells, a new clue and a more convenient means can be provided for early diagnosis of tumors.
Disclosure of Invention
The inventor of the application unexpectedly discovers a miRNA molecular marker which can be accurately and stably used for screening, predicting, diagnosing or prognosing the bile duct cancer for the first time through exploratory research on miRNA in the circulating blood exosomes of the bile duct cancer patient.
Based on this, in one aspect, the present application provides a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma comprising means or reagents for specifically detecting one or more miRNA markers selected from the group consisting of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
In particular embodiments, the kits, microarrays or biochips provided herein wherein the included means or reagents further comprise primers and/or probes capable of specifically detecting the miRNA markers.
In a specific embodiment, the primer and/or probe sequence of the marker miR-151a-5p is: ucgaggagcucacagucuagu, respectively; the primer and/or probe sequence of the marker miR-191-5p is as follows: caacggaaucccaaaagcagcug, respectively; the primer and/or probe sequence of the marker miR-4732-3p is as follows: gcccugaccuguccuguucug are provided.
In another aspect, the present application provides a use of a miRNA marker for the preparation of a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma, wherein the miRNA marker is selected from one or more of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
In yet another aspect, the present application provides the use of a tool or reagent for specifically detecting miRNA markers for the preparation of a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma, wherein the miRNA markers are selected from one or more of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
In a further aspect, the present application provides the use of primers and/or probes for specifically detecting miRNA markers for the preparation of a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma, wherein the miRNA markers are selected from one or more of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
In particular embodiments, the miRNA markers to which the present application relates are selected from one or more of: initial miR-151a-5p, precursor miR-151a-5p, mature miR-151a-5p, initial miR-191-5p, precursor miR-191-5p, mature miR-191-5p, initial miR-4732-3p, precursor miR-4732-3p, and mature miR-4732-3 p.
In particular embodiments, the initial miR-151a-5p, the initial miR-191-5p, and the initial miR-4732-3p are capable of being cleaved and expressed intracellularly into the corresponding mature miR-151a-5p, mature miR-191-5p, mature miR-4732-3 p; the precursor miR-151a-5p, the precursor miR-191-5p and the precursor miR-4732-3p can be cut and expressed into corresponding mature miR-151a-5p, mature miR-191-5p and mature miR-4732-3p in cells.
In another specific embodiment, the miRNA markers to which the present application relates are derived from circulating blood exosomes of the subject.
Compared with the existing molecular marker, the miRNA molecular marker provided by the application can accurately screen, predict, diagnose or prognose the occurrence and development of bile duct cancer, and has the characteristics of rapidness and stability.
Products or tools, such as kits, microarrays, biochips, or other similar detection tools, prepared based on the miRNA molecular markers provided herein can be used for screening, predicting, diagnosing, or prognosing cholangiocarcinoma by rapid detection of circulating blood in a subject. The method and the related products thereof have high specificity, sensitivity and accuracy.
Drawings
FIG. 1 shows the total miRNA expression after calibration in the circulating blood exosomes of cholangiocarcinoma patients.
FIG. 2 shows the miRNA expression level of circulating blood exosomes of cholangiocarcinoma patients.
FIG. 3 is a diagram of further detecting the expression level of miRNA with high expression in the circulating blood exosomes of cholangiocarcinoma patients by enlarging samples.
FIG. 4 shows the expression level of high-expression miRNA in the circulating blood exosomes after bile duct cancer patient surgery.
Fig. 5 shows the accuracy of predicting cholangiocarcinoma by high-expression miRNA.
Detailed Description
Cholangiocarcinoma is an important biliary tract malignant tumor, specific miRNA is reported for cholangiocarcinoma, and especially, identification of exosome miRNA secreted into circulating blood by cholangiocarcinoma cells is still blank.
The inventor of the application screens and verifies that the miRNA in the circulating blood exosomes is used for predicting the occurrence and development of the bile duct cancer for the first time.
Specifically, the inventor of the application unexpectedly discovers specific high-expression miRNA in circulating blood exosomes of a batch of cholangiocarcinoma patients through high-throughput sequencing based on samples of Chinese people (mainly Han).
Further, the inventor verifies that the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in the blood exosomes of the cholangiocarcinoma patients are obviously higher than the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in the blood exosomes of normal people through scale-up, and the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in circulating blood exosomes of patients with bile duct cancer after surgery are remarkably reduced, which indicates that miR-151a-5p, miR-191-5p and miR-4732-3p in circulating blood exosomes can be used as markers for screening, predicting, diagnosing or prognosing bile duct cancer, and provides a basis for the establishment of a clinical scheme for preventing or treating bile duct cancer. For example, if the expression level of any one or more of circulating blood exosomes miR-151a-5p, miR-191-5p or miR-4732-3p of the subject is increased, the subject can be judged to be at risk of having cholangiocarcinoma or to have cholangiocarcinoma; if the expression quantity of any one or more of the circulating blood exosomes miR-151a-5p, miR-191-5p or miR-4732-3p of the treated biliary duct cancer patient is reduced, the treatment effect of the biliary duct cancer patient can be judged to be good or the biliary duct cancer patient does not relapse.
Based on this, the inventors of the present application have developed products or tools, including kits, microarrays, biochips, or other similar detection tools, that can be used for rapid and accurate screening, prediction, diagnosis, or prognosis of cholangiocarcinoma.
For a better understanding of the present disclosure, reference will now be made to the following detailed description taken in conjunction with the accompanying drawings. It should be understood that these examples are for further illustration only and are not intended to limit the scope of the present application. In addition, after reading the contents of the present application, some insubstantial changes or modifications of the present application will still fall within the scope of the present application.
The experimental procedures in the following examples are, unless otherwise specified, routine in the art.
Example 1
The embodiment provides a method for identifying miRNA specifically and highly expressed in circulating blood exosomes of cholangiocarcinoma patients through high-throughput sequencing. The specific method is as follows: the value of Xue Xinying is the value of Xue Xinying,et al., Exosomal miRNA profiling before andafter surgery revealed potential diagnostic and prognostic markers for lungadenocarcinoma，Acta Biochim Biophys Sin (Shanghai), Vol. 52, No. 3, Pages281-293, 2020。
the sampled patient information is shown in table 1.
Figure DEST_PATH_IMAGE001
TABLE 1
The total expression quantity of miRNA after calibration in the circulating blood exosomes of the patients with bile duct cancer is shown in figure 1.
The results show that the miRNA highly expressed in the circulating blood exosomes of the patients with the bile duct cancer comprises the following components: miR-1-3p, miR-96-5p, miR-151a-5p, miR-191-5p, miR-192-5p, miR-182-5p, NC-000010.11-21778, miR-4732-3p, miR-26a-5p and miR-146b-5p, and the specific data please refer to figure 2.
Example 2
This example further verifies the high expression of miRNA in the circulating blood exosomes of the patients with cholangiocarcinoma identified in example 1 by expanding the sample.
Specifically, by comparing the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in the blood exosomes of 40 normal persons and 45 bile duct cancer patients, it was found that the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in the blood exosomes of the bile duct cancer patients were significantly higher than the levels of miR-151a-5p, miR-191-5p and miR-4732-3p in the blood exosomes of the normal persons, as shown in FIG. 3.
Example 3
The example further tests the expression quantity of miR-151a-5p, miR-191-5p and miR-4732-3p in circulating blood exosomes of patients with cholangiocarcinoma after receiving surgical treatment.
miR-151a-5p, miR-191-5p and miR-4732-3p in circulating blood exosomes of cholangiocarcinoma patients are remarkably reduced after surgery, as shown in FIG. 4.
Example 4
In this example, the accuracy and specificity of miR-151a-5p, miR-191-5p and miR-4732-3p for predicting cholangiocarcinoma are evaluated, and the specific method please refer to: the sum of the Xi Chen and the Xi Chen,et al., Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases,Cell Research, No. 10, Page 997-1006, 2008。
as shown in FIG. 5, the specificity and accuracy of predicting the bile duct cancer by the miR-151a-5p, miR-191-5p and miR-4732-3p in the circulating blood exosomes of the patients with the bile duct cancer are high, particularly the AUC of the bile duct cancer predicted by the miR-151a-5p is 0.8694, and the prediction model is excellent.
The above description is not intended to limit the present application, nor is the present application limited to the above examples. Those skilled in the art should also realize that such changes, modifications, additions and substitutions are within the spirit and scope of the present application.

Claims (8)

1. A kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma comprising means or reagents for specifically detecting one or more miRNA markers selected from the group consisting of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
2. The kit, microarray or biochip of claim 1, wherein the means or reagents comprise primers and/or probes capable of specifically detecting the miRNA markers.
3. The kit, microarray or biochip of claim 1 or 2, wherein the miRNA markers are selected from one or more of: initial miR-151a-5p, precursor miR-151a-5p, mature miR-151a-5p, initial miR-191-5p, precursor miR-191-5p, mature miR-191-5p, initial miR-4732-3p, precursor miR-4732-3p, and mature miR-4732-3 p.
4. The kit, microarray or biochip of claim 1 or 2, wherein the miRNA marker is from a circulating blood exosome of a subject.
Use of a miRNA marker for the preparation of a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma, wherein the miRNA marker is selected from one or more of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
6. Use of a tool or reagent for the specific detection of a miRNA marker for the manufacture of a kit, microarray or biochip for screening, predicting, diagnosing or prognosing cholangiocarcinoma, wherein the miRNA marker is selected from one or more of: miR-151a-5p, miR-191-5p, and miR-4732-3 p.
7. The use of claim 5 or 6, wherein the miRNA marker is selected from one or more of: initial miR-151a-5p, precursor miR-151a-5p, mature miR-151a-5p, initial miR-191-5p, precursor miR-191-5p, mature miR-191-5p, initial miR-4732-3p, precursor miR-4732-3p and mature miR-4732-3 p.
8. The use of claim 5 or 6, wherein the miRNA marker is from a circulating blood exosome of the subject.
CN202010458316.0A 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof Active CN111363829B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010458316.0A CN111363829B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof
CN202010799217.9A CN111748635B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010458316.0A CN111363829B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010799217.9A Division CN111748635B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof

Publications (2)

Publication Number Publication Date
CN111363829A true CN111363829A (en) 2020-07-03
CN111363829B CN111363829B (en) 2020-09-22

Family

ID=71205866

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010799217.9A Active CN111748635B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof
CN202010458316.0A Active CN111363829B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010799217.9A Active CN111748635B (en) 2020-05-27 2020-05-27 miRNA marker of bile duct cancer and application thereof

Country Status (1)

Country Link
CN (2) CN111748635B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114990216A (en) * 2022-05-31 2022-09-02 山东大学齐鲁医院 Application of micro RNA molecules as biomarkers in bile duct cancer prognosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036429A1 (en) * 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
EP3239303A1 (en) * 2016-04-26 2017-11-01 Advanced Marker Discovery, S.L. In vitro method for identifying pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas
CN107385035A (en) * 2017-07-18 2017-11-24 深圳大学 The serum/plasma miRNA marker related to diabetes B PVR and its application
CN107475363A (en) * 2017-06-26 2017-12-15 深圳大学 Biomarker combination, the screening and its application of biomarker combination of a kind of non-small cell lung cancer
CN110564852A (en) * 2019-08-06 2019-12-13 中国医学科学院血液病医院(中国医学科学院血液学研究所) MiRNAs expression map model related to human multiple myeloma, construction method and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112029863A (en) * 2014-06-11 2020-12-04 东丽株式会社 Detection kit or device for biliary tract cancer and detection method
EP3763826A4 (en) * 2018-02-22 2021-06-30 Osaka University Analysis/diagnosis method utilizing rna modification
CN112867802B (en) * 2018-09-20 2024-06-04 塔微核酸有限责任公司 MicroRNA signatures for predicting liver dysfunction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036429A1 (en) * 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
EP3239303A1 (en) * 2016-04-26 2017-11-01 Advanced Marker Discovery, S.L. In vitro method for identifying pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas
CN107475363A (en) * 2017-06-26 2017-12-15 深圳大学 Biomarker combination, the screening and its application of biomarker combination of a kind of non-small cell lung cancer
CN107385035A (en) * 2017-07-18 2017-11-24 深圳大学 The serum/plasma miRNA marker related to diabetes B PVR and its application
CN110564852A (en) * 2019-08-06 2019-12-13 中国医学科学院血液病医院(中国医学科学院血液学研究所) MiRNAs expression map model related to human multiple myeloma, construction method and application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAO LI等: "MicroRNA -191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma", 《HEPATOLOGY》 *
MEGAN E. MCNALLY等: "Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma", 《INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114990216A (en) * 2022-05-31 2022-09-02 山东大学齐鲁医院 Application of micro RNA molecules as biomarkers in bile duct cancer prognosis

Also Published As

Publication number Publication date
CN111363829B (en) 2020-09-22
CN111748635A (en) 2020-10-09
CN111748635B (en) 2022-07-29

Similar Documents

Publication Publication Date Title
JP6140202B2 (en) Gene expression profiles to predict breast cancer prognosis
CN107326066B (en) Urine markers for detection of bladder cancer
CN102333887B (en) Method for detecting metastasis of gi cancer
CN109161593B (en) Application of circular RNA and microRNA in colorectal cancer screening and diagnosis
Ke et al. Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer
CN112921083A (en) Genetic markers in the assessment of intestinal polyps and colorectal cancer
CN111363829B (en) miRNA marker of bile duct cancer and application thereof
CN111733236A (en) PiRNA marker of bile duct cancer and gallbladder cancer and application thereof
US7759060B2 (en) Molecular method for diagnosis of prostate cancer
Taniguchi et al. Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction
Hamada et al. Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas
CN111763736B (en) Liquid biopsy kit for diagnosing thyroid papillary carcinoma lymph node metastasis
Grätz et al. A pipeline for the development and analysis of extracellular vesicle-based transcriptomic biomarkers in molecular diagnostics
CN113151465A (en) Products and related applications for identifying polyps and cancers based on genetic markers
JP2020072705A (en) Urine markers for detection of bladder cancer
AU2015200982A1 (en) Urine markers for detection of bladder cancer
AU2020200168A1 (en) Urine markers for detection of bladder cancer
CN110004231A (en) Kidney excretion body marker group and its application
RU2757347C1 (en) Method for differential diagnosis of nodular formations of the human thyroid gland
CN116987788B (en) Method and kit for detecting early lung cancer by using flushing liquid
JP2004248508A (en) Hurp gene as molecular marker for bladder cancer
CN110331206A (en) The gene marker and application thereof of auxiliary diagnosis adenocarcinoma of lung
KR20230020820A (en) Biomarkers for diagnosing breast cancer and uses thereof
WO2020188564A1 (en) Prognostic and treatment methods for prostate cancer
CN112980959A (en) Genetic markers for predicting or diagnosing colorectal cancer/colorectal cancer risk

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant